+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epilepsy Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027

  • ID: 4851661
  • Report
  • Region: Global
  • 166 pages
  • Transparency Market Research
1 of 2

Global Epilepsy Therapeutics Market: Overview

This report analyzes the global epilepsy therapeutics market in terms of its current and future scenario. Epilepsy is a central nervous system disorder in which the brain activity becomes abnormal, thereby resulting in periods of unusual behavior or seizures, sensations, and sometimes, even loss of awareness. Epilepsy is generally diagnosed after a person has experienced at least two seizures that didn’t occur due to known medical condition; for instance, extremely low blood sugar or alcohol withdrawal. The treatment of epilepsy can be carried out with antiepileptic medications (AEDs), diet therapy, and surgery. Epilepsy therapeutics or medications are the starting treatment choice for almost all patients with multiple seizures. According to American Association of Neurological Surgeons, epilepsy therapeutics are significantly effective and completely control seizures in a majority (approximately 70%) of patients. The drugs prevent seizures by decreasing the tendency of the brain cells to send excessive and confused electrical impulses. 

This report on the global epilepsy therapeutics market comprises an elaborate executive summary, including a market snapshot that provides information about different segments of the market. The report also provides information and data analysis of the global market with respect to its segments based on product, distribution channel, and geography. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Moreover, the section comprises the company profiles with a business overview to project the competitive landscape of the market. It also provides market attractiveness analysis in terms of geography, and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the epilepsy therapeutics market. 

Global Epilepsy Therapeutics Market: Key Segments

Based on product, the global epilepsy therapeutics market has been segmented into first generation epilepsy therapeutics, second generation epilepsy therapeutics, and third generation epilepsy therapeutics. In terms of distribution channel, the global epilepsy therapeutics market has been classified into hospital pharmacy, retail pharmacy, and online pharmacy. The global epilepsy therapeutics market has been analyzed based on approvals and launches of products, research and developmental activities, and presence of key players in the region. Market size and forecast for each of these segments have been provided for the period of 2017 to 2027, along with their respective CAGR for the forecast period from 2019 to 2027, considering 2018 as the base year. 

Global Epilepsy Therapeutics Market: Regional Outlook

In terms of region, the global epilepsy therapeutics  market has been categorized into five major regions and key countries in these regions: North America (the U.S., Canada), Europe (Germany, the U.K., France, Italy, Russia, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC countries, South Africa, Israel, and Rest of Middle East & Africa). Market size and forecast for each of these regions and their key countries have been provided for the period from 2017 to 2027, along with their respective CAGR for the forecast period 2019-2027, considering 2018 as the base year. This report also covers the competitive scenario of the market in these regions. 

Companies Mentioned in Report

The report profiles major players operating in the global epilepsy therapeutics market in terms of attributes such as company overview, financial overview, product portfolio, and business strategies. Major companies profiled in this report are Pfizer, Inc., UCB S.A., Bausch Health Companies Inc., Novartis AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., Eisai Co., Upsher-Smith Laboratories, LLC., and Amneal Pharmaceuticals LLC. 

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Epilepsy Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Epilepsy Therapeutics Market Analysis and Forecast, 2017-2027
4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook
5.1.Pipeline
5.2.Epidemiology of Epilepsy
5.3.Key Industry Events

6. Global Epilepsy Therapeutics Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Global Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
6.3.1. First Generation Epilepsy Therapeutics
6.3.2. Second Generation Epilepsy Therapeutics
6.3.3. Third Generation Epilepsy Therapeutics
6.4. Global Epilepsy Therapeutics Market Attractiveness, by Product

7. Global Epilepsy Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Global Epilepsy Therapeutics Market Attractiveness, by Distribution Channel

8. Global Epilepsy Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Epilepsy Therapeutics Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Epilepsy Therapeutics Market Attractiveness, by Region

9. North America Epilepsy Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
9.2.1. First Generation Epilepsy Therapeutics
9.2.2. Second Generation Epilepsy Therapeutics
9.2.3. Third Generation Epilepsy Therapeutics
9.3. North America Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. North America Epilepsy Therapeutics Market Value Forecast, by Country, 2017-2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Epilepsy Therapeutics Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Epilepsy Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
10.2.1. First Generation Epilepsy Therapeutics
10.2.2. Second Generation Epilepsy Therapeutics
10.2.3. Third Generation Epilepsy Therapeutics
10.3. Europe Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Europe Epilepsy Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Epilepsy Therapeutics Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Epilepsy Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Asia Pacific Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
11.2.1. First Generation Epilepsy Therapeutics
11.2.2. Second Generation Epilepsy Therapeutics
11.2.3. Third Generation Epilepsy Therapeutics
11.3. Asia Pacific Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4. Asia Pacific Epilepsy Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Epilepsy Therapeutics Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Epilepsy Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Latin America Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
12.2.1. First Generation Epilepsy Therapeutics
12.2.2. Second Generation Epilepsy Therapeutics
12.2.3. Third Generation Epilepsy Therapeutics
12.3. Latin America Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Pharmacy
12.4. Latin America Epilepsy Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Epilepsy Therapeutics Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Epilepsy Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Epilepsy Therapeutics Market Value Forecast, by Product, 2017-2027
13.2.1. First Generation Epilepsy Therapeutics
13.2.2. Second Generation Epilepsy Therapeutics
13.2.3. Third Generation Epilepsy Therapeutics
13.3. Middle East & Africa Epilepsy Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Online Pharmacy
13.4. Middle East & Africa Epilepsy Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5. Middle East & Africa Epilepsy Therapeutics Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1.Market Player - Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis By Company (2018)
14.3. Company Profiles
14.3.1. Pfizer, Inc.
14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3.Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. UCB S.A.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Bausch Health Companies Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Novartis AG
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. GlaxoSmithKline plc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Teva Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Sunovion Pharmaceuticals Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Eisai Co., Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Upsher-Smith Laboratories, LLC.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Amneal Pharmaceuticals LLC.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Company Financials
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll